復宏漢霖(02696.HK)與Sermonix達成戰略合作 開發新型乳腺癌內分泌療法
復宏漢霖(02696.HK)與Sermonix宣布達成戰略合作和獨佔許可協議,以在中國開發、生產和商業化後者的核心在研產品lasofoxifene。
根據協議條款,復宏漢霖將獲得lasofoxifene在合作區域內,用於至少兩項ER+/HER2-乳腺癌適應症的獨佔權利和分許可權,Sermonix將保留其他全球區域的權利。Sermonix將從本次合作中獲得首付款及可達5,800萬美元的里程碑付款,並享有在復宏漢霖區域的銷售分成。(ca/cy)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.